钙化性与风湿性二尖瓣病变中修复与置换的比较
基于波兰国家心脏手术登记处2006至2020年数据,纳入4338例风湿性或钙化性二尖瓣病变患者,比较修复与置换的远期生存。无二尖瓣狭窄患者修复改善生存(HR 0.81;95%CI 0.68-0.97;P=.022),二尖瓣狭窄患者修复无获益(HR 1.17;95%CI 0.85-1.59;P=.332)。
要点
- 无二尖瓣狭窄者修复改善生存(HR 0.81;95%CI 0.68-0.97;P=.022)。
- 二尖瓣狭窄者修复对生存无影响(HR 1.17;95%CI 0.85-1.59;P=.332)。
- 10年免于二尖瓣再手术率修复与置换组间无显著差异。
核心结论
- 无二尖瓣狭窄的风湿性/钙化性二尖瓣病变患者,修复应为首选;存在二尖瓣狭窄时修复无获益。
研究设计与样本
- 基于波兰国家心脏手术登记处2006至2020年数据的队列研究,纳入4338例风湿性或钙化性二尖瓣病变行修复或置换的患者。
- 排除除冠状动脉旁路移植或三尖瓣手术外的附加手术、再次手术及急诊病例;远期生存通过国家健康基金登记数据核实。
- 在全队列及倾向性评分匹配后比较修复与置换的生存。
主要发现
- 共4338例:单纯二尖瓣反流1859例(43%),二尖瓣狭窄2479例(57%)。
- 单纯反流组修复543例(29%),狭窄组修复126例(5.1%)(P<.001)。
- 984例(23%)同期行冠状动脉旁路移植,1358例(32%)行三尖瓣手术。
- 无二尖瓣狭窄患者修复改善生存(HR 0.81;95%CI 0.68-0.97;P=.022),二尖瓣狭窄患者无影响(HR 1.17;95%CI 0.85-1.59;P=.332);倾向性匹配队列证实上述结果。
- 无狭窄者10年免于二尖瓣再手术率修复95.5%±1.2% vs 置换96.0%±0.7%(P=.416);狭窄者修复91.8%±3.4% vs 置换95.9%±0.5%(P=.065)。
临床怎么用
- 作者认为,无二尖瓣狭窄的风湿性/钙化性二尖瓣病变患者,修复应为首选选项;存在二尖瓣狭窄时修复不带来获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of repair over replacement of rheumatic or calcified mitral valve (MV) is debatable. METHODS: Patients who underwent MV repair or replacement for rheumatic or calcified MV disease between 2006 and 2020 were identified in the Polish National Registry of Cardiac Surgery Procedures. Patients who underwent additional procedures other than coronary artery bypass grafting or tricuspid valve surgery, as well as redo or emergency cases, were excluded. The long-term survival was verified based on National Health Fund registry data. The survival was compared between MV repair and replacement in the whole cohort and after propensity score matching. RESULTS: We included 4338 patients: 1859 (43%) with pure mitral regurgitation and 2479 (57%) with mitral stenosis. MV was repaired in 543 patients (29%) with pure regurgitation and 126 (5.1%) with stenosis (P < .001). In total, 984 (23%) patients underwent concomitant coronary artery bypass grafting and 1358 (32%) tricuspid valve surgery. MV repair improved survival (hazard ratio 0.81; 95% CI 0.68-0.97; P = .022) in patients with no mitral stenosis, and had no effect in mitral stenosis (hazard ratio 1.17; 95% CI 0.85-1.59; P = .332). The results were confirmed in propensity-matched cohorts. The freedom from MV reoperation at 10 years was 95.5% ± 1.2% after repair and 96.0% ± 0.7% after MV replacement (P = .416) in the absence of stenosis and 91.8% ± 3.4% after repair vs 95.9% ± 0.5% after replacement in patients with mitral stenosis (P = .065). CONCLUSIONS: Repair of rheumatic/calcified mitral valve should be a preferred option in patients with no mitral stenosis, but confers no benefit if mitral stenosis is present.
引用
- Deja MA, Malinowski M, Widenka K, et al. Comparison of Repair vs Replacement in Calcific and Rheumatic Mitral Disease. Ann Thorac Surg. 2023. PMID: 37271445. doi:10.1016/j.athoracsur.2023.04.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。